<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580628</url>
  </required_header>
  <id_info>
    <org_study_id>202000549</org_study_id>
    <nct_id>NCT04580628</nct_id>
  </id_info>
  <brief_title>Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)</brief_title>
  <official_title>Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Saint-Hilaire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Saint-Hilaire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thuflep TLF: initial experience and results of prostate laser enucleation with fibrous&#xD;
      thulium laser (TLF)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While prostate laser enucleation is being confirmed as the new gold standard for surgical&#xD;
      management of benign prostate hypertrophy, the holmium:Yag laser is currently the most widely&#xD;
      used. A new laser technology, the fibrous thulium laser (TFL), has recently appeared with&#xD;
      clearly superior results for lithotripsy. The question therefore arises of the surgical and&#xD;
      functional results of the use of fibrous thulium for prostate enucleation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL</measure>
    <time_frame>MONTH 12</time_frame>
    <description>self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of post-operative complications</measure>
    <time_frame>MONTH 6</time_frame>
    <description>post operative complications : urethral stenosis, prostate bed sclerosis, overactive bladder, urinary incontinence, erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of intervention</measure>
    <time_frame>POST SURGERY HOUR 24</time_frame>
    <description>in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bloodloss assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>measurement of haemoglobinemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>max flow assessment</measure>
    <time_frame>MONTH 12</time_frame>
    <description>measured with urinary flowmeter in ml/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>max flow assessment</measure>
    <time_frame>MONTH 6</time_frame>
    <description>measured with urinary flowmeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>max flow assessment</measure>
    <time_frame>MONTH 3</time_frame>
    <description>measured with urinary flowmeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>max flow assessment</measure>
    <time_frame>MONTH 1</time_frame>
    <description>measured with urinary flowmeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-void residual (PVR) urine test</measure>
    <time_frame>MONTH 12</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-void residual (PVR) urine test</measure>
    <time_frame>MONTH 6</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-void residual (PVR) urine test</measure>
    <time_frame>MONTH 3</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-void residual (PVR) urine test</measure>
    <time_frame>MONTH 1</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>erectile dysfunction assessment</measure>
    <time_frame>MONTH 12</time_frame>
    <description>self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>erectile dysfunction assessment</measure>
    <time_frame>MONTH 6</time_frame>
    <description>self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>erectile dysfunction assessment</measure>
    <time_frame>MONTH 3</time_frame>
    <description>self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>erectile dysfunction assessment</measure>
    <time_frame>MONTH 1</time_frame>
    <description>self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>MONTH 12</time_frame>
    <description>self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>MONTH 6</time_frame>
    <description>self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>MONTH 3</time_frame>
    <description>self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>MONTH 1</time_frame>
    <description>self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary incontinence Assessment</measure>
    <time_frame>MONTH 12</time_frame>
    <description>self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary incontinence Assessment</measure>
    <time_frame>MONTH 6</time_frame>
    <description>self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary incontinence Assessment</measure>
    <time_frame>MONTH 3</time_frame>
    <description>self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary incontinence Assessment</measure>
    <time_frame>MONTH 1</time_frame>
    <description>self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA in ng/mL level evolution</measure>
    <time_frame>MONTH 1</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL</measure>
    <time_frame>MONTH 1</time_frame>
    <description>self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL</measure>
    <time_frame>MONTH 3</time_frame>
    <description>self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL</measure>
    <time_frame>MONTH 6</time_frame>
    <description>self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENT GLOBAL IMPRESSION OF IMPROVEMENT</measure>
    <time_frame>MONTH 1</time_frame>
    <description>SELF REPORT SATISFACTION QUESTIONARY FROM 1 (better condition ) to 7 ( worse condition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENT GLOBAL IMPRESSION OF SEVERITY</measure>
    <time_frame>MONTH 1</time_frame>
    <description>SELF REPORT SATISFACTION QUESTIONARY FROM 1( normal )to 4 (severe )</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Hyperplasia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all patients treated at clinique saint hilaire Rouen with Thuflep, who consent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients superior or equal to 18 years old&#xD;
&#xD;
          -  Benign Prostate Hypertrophy ( more than 30cc.)&#xD;
&#xD;
          -  Indication to surgical treatment&#xD;
&#xD;
          -  No contraindication for surgery&#xD;
&#xD;
          -  No opposition to participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of urethral stenosis&#xD;
&#xD;
          -  Evidence of a bladder tumour&#xD;
&#xD;
          -  Evidence of prostate cancer known or confirmed by prostate biopsies if suspected&#xD;
&#xD;
          -  Known neurological bladder&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BENOIT MALVAL</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Saint-Hilaire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BENOIT MALVAL, MD</last_name>
    <phone>+33276512121</phone>
    <email>bmalval@clinique-sainthilaire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FRANCOISE HUPEL</last_name>
    <phone>+33276512121</phone>
    <email>fhupel@clinique-sainthilaire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FRANCOISE HUPEL</last_name>
      <phone>+33276512121</phone>
      <email>fhupel@clinique-sainthilaire.fr</email>
    </contact>
    <investigator>
      <last_name>BENOIT MALVAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ISMAEL GALLIOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Saint-Hilaire</investigator_affiliation>
    <investigator_full_name>MALVAL Benoit</investigator_full_name>
    <investigator_title>Principal Investigator, Doctor in urology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

